| Code | 2350F | ||||||||||
| MA number | 44/0448/25-S | ||||||||||
| Product Form: | cps dur 30x1x10 mg (blis.OPA/Al/PVC/PE/Al - jednotk.bal.) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Egis Pharmaceuticals PLC, Hungary | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 08.01.2026 |
| Validity: | 08.01.2031 |
| Pediatric posology: | Yes |
| SPC: |
SPC_Lentulil 4 mg, 10 mg_cps dur_12/2025_REG.pdf
|
| PIL: |
PIL_Lentulil 4 mg, 10 mg_cps dur_12/2025_REG.pdf
|
| Safety feature | Yes |
| Data update: | 27.01.2026 |
